Начало・Списък с акции・Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Затворен

СекторЗдравеопазване

4.37 1.63

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.29

Максимум

4.47

Ключови измерители
By Trading Economics
Приходи	-7.1M -79M
Продажби	-15M 71M
EPS	-0.19
Марж на печалбата	-110.661
Служители	975
EBITDA	-3.4M -71M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+126.85% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	208M 1.9B
Предишно отваряне	2.74
Предишно затваряне	4.37

Настроения в новините

By Acuity

34%

66%

130 / 340 Класиране в Healthcare

Iovance Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 19:51 ч. UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3.08.2026 г., 19:51 ч. UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31.07.2026 г., 23:41 ч. UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30.07.2026 г., 23:51 ч. UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29.07.2026 г., 15:16 ч. UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28.07.2026 г., 23:56 ч. UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27.07.2026 г., 19:36 ч. UTC

Social Media

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24.07.2026 г., 19:12 ч. UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22.07.2026 г., 23:11 ч. UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

21.07.2026 г., 19:46 ч. UTC

Social Media

Iovance Biotherapeutics shares are higher amid positive social media sentiment and favorable earnings reports from peers, including General Motors and Novartis.

20.07.2026 г., 19:16 ч. UTC

Social Media

Iovance Biotherapeutics Inc shares are higher today, with significant trading volume reaching 23.48 million. The stock has fluctuated between 4.44 and 5.07 during the session.

Сравнение с други в отрасъла

Ценова промяна

Iovance Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

126.85% нагоре

12-месечна прогноза

Среден 9.8 USD 126.85%

Висок 14 USD

Нисък 5 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Iovance Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Iovance Biotherapeutics Inc през последните 3 месеца.

Настроение

By Acuity

130 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.